Alnylam Pharmace. buy Commando
Start price
20.08.22
/
50%
€214.90
Target price
20.08.23
-
Performance (%)
-14.30%
End price
07.03.23
€184.16
Summary
This prediction ended on 07.03.23 with a price of €184.16. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -14.30%. Commando has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 5.228% | 5.228% | -25.629% |
| iShares Core DAX® | 3.178% | 0.980% | 15.331% |
| iShares Nasdaq 100 | 2.972% | 0.925% | 39.831% |
| iShares Nikkei 225® | 0.545% | -4.556% | 17.661% |
| iShares S&P 500 | 2.367% | 0.833% | 30.000% |
Comments by Commando for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.